文献速递胰腺与胆道疾病消化道肿瘤与早癌

覆膜与裸双层自膨式金属支架用于不可切除肝外恶性胆道梗阻姑息治疗的随机对照多中心试验

Covered versus uncovered double bare self-expandable metal stent for palliation of unresectable extrahepatic malignant biliary obstruction: a randomized controlled multicenter trial.
PubMed 文献 · Gastrointest Endosc · 2022-09-07

多中心随机对照试验纳入258例远端恶性胆道梗阻患者,比较部分覆膜双层金属支架(PCDBS,130例)与裸双层金属支架(UCDBS,128例)的支架通畅性。PCDBS平均通畅时间421.2天(95%CI 346.7-495.7)长于UCDBS的377.4天(95%CI 299.7-455.0),但两组总支架功能障碍及6个月内支架功能障碍无差异。作者认为PCDBS相比UCDBS在支架通畅性和总生存方面的获益不明确,尽管PCDBS肿瘤内生长发生率更低。

要点

  • PCDBS平均支架通畅时间421.2天(95%CI 346.7-495.7)长于UCDBS的377.4天(95%CI 299.7-455.0)。
  • 两组总支架功能障碍及6个月内支架功能障碍无差异。
  • PCDBS肿瘤内生长发生率更低,但支架通畅性和总生存获益不明确。

核心结论

  • 在远端恶性胆道梗阻患者中,PCDBS相比UCDBS在支架通畅性和总生存方面的获益不明确,尽管PCDBS肿瘤内生长发生率更低。

研究设计与样本

  • 多中心随机对照试验,纳入258例远端恶性胆道梗阻患者,PCDBS组130例,UCDBS组128例。

主要发现

  • PCDBS平均支架通畅时间421.2天(95%CI 346.7-495.7)长于UCDBS的377.4天(95%CI 299.7-455.0)。
  • 两组总支架功能障碍和6个月内支架功能障碍无差异。
  • 多因素分析显示支架置入后化疗是总生存的显著因素(HR 0.570;95%CI 0.408-0.796),对支架通畅性有边缘性影响(HR 1.569;95%CI 0.923-2.667)。
  • 两组胰腺炎、胆囊炎和支架移位等不良事件无显著差异。
  • PCDBS肿瘤内生长发生率更低。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: In a recent randomized controlled trial, a double bare metal stent (DBS) showed better stent patency than single-layer metal stents. However, clear evidence comparing the efficacy of uncovered (UCDBS) and partially covered (PCDBS) DBSs for distal malignant biliary obstruction (MBO) is lacking. Therefore, we compared the clinical outcomes including stent patency of UCDBSs versus PCDBSs. METHODS: A multicenter, randomized study was performed in patients with distal MBO. The primary endpoint was stent patency. Secondary endpoints were the proportion of patients with patent stents at 6 months, risk factors for stent dysfunction, overall survival, technical and clinical success rates of stent placement, and other adverse events (AEs). RESULTS: Among 258 included patients, 130 were randomly assigned to the PCDBS group and 128 to the UCDBS group. The mean duration of stent patency of the PCDBS (421.2 days; 95% confidence interval [CI], 346.7-495.7) was longer than that of the UCDBS (377.4 days; 95% CI, 299.7-455.0), although total stent dysfunction and stent dysfunction within 6 months were not different between groups. Multivariate analysis indicated that chemotherapy after stent placement was a significant factor for overall survival (hazard ratio, .570; 95% CI, .408-.796) and had a marginal impact on stent patency (hazard ratio, 1.569; 95% CI, .923-2.667). There were no remarkable differences in AEs, including pancreatitis, cholecystitis, and stent migration, between the 2 groups. CONCLUSIONS: The use of PCDBSs compared with UCDBSs in patients with distal MBO has unclear benefits regarding stent patency and overall survival, although PCDBSs have a lower rate of tumor ingrowth. (Clinical trial registration number: NCT02937246.).

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Park SW, Lee KJ, Chung MJ, et al. Covered versus uncovered double bare self-expandable metal stent for palliation of unresectable extrahepatic malignant biliary obstruction: a randomized controlled multicenter trial. Gastrointest Endosc. 2022. PMID: 36084714. doi:10.1016/j.gie.2022.08.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。